Prostate Cancer Screening and Post Treatment Monitoring

  • Sanchia S. Goonewardene
  • Raj Persad
Chapter

Abstract

Prostate cancer screening research in the UK is based upon a 2013 Cochrane review of evidence. This demonstrated that a prostate cancer screening programme did not improve or worsen mortality from prostate cancer. As a result, the evidence is inconclusive as to whether a screening programme is required or not.

Prostate cancer screening research in the UK is based upon a 2013 Cochrane review of evidence. This demonstrated that a prostate cancer screening programme did not improve or worsen mortality from prostate cancer. As a result, the evidence is inconclusive as to whether a screening programme is required or not.

After radical treatment of either prostatectomy, radiotherapy or brachytherapy. Patients are monitored for recurrence by a blood test examining Prostate Specific Antigen (PSA). This would be followed up at a clinic appointment. PSA is an enzyme produced by the prostate gland. This is usually checked every 3 months for the first year, then every 6 months for the next 3 years (EAU guidelines 2012). Post radical surgery, a PSA of greater than 0.2 ng/mL is indicative of ‘biochemical,’ recurrence (EAU guidelines 2012). This is interpreted to mean recurrence of cancer. After radiotherapy or brachytherapy, the PSA level defining biochemical recurrence is defined as ‘2 plus the lowest PSA level after treatment’ (known as ‘the nadir’).

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Sanchia S. Goonewardene
    • 1
  • Raj Persad
    • 2
  1. 1.The Royal Free Hospital and UCLLondonUnited Kingdom
  2. 2.North Bristol NHS TrustBristolUnited Kingdom

Personalised recommendations